HealthCor Management L.P. lowered its stake in shares of Bioverativ Inc (NASDAQ:BIVV) by 9.6% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 3,750,000 shares of the biotechnology company’s stock after selling 400,000 shares during the period. Bioverativ makes up approximately 6.6% of HealthCor Management L.P.’s holdings, making the stock its 2nd biggest position. HealthCor Management L.P. owned approximately 3.47% of Bioverativ worth $202,200,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds also recently bought and sold shares of BIVV. BlackRock Inc. increased its position in shares of Bioverativ by 16.9% during the 4th quarter. BlackRock Inc. now owns 10,845,635 shares of the biotechnology company’s stock valued at $584,795,000 after purchasing an additional 1,567,638 shares during the last quarter. Old Mutual Global Investors UK Ltd. increased its position in shares of Bioverativ by 47.8% during the 4th quarter. Old Mutual Global Investors UK Ltd. now owns 2,507,002 shares of the biotechnology company’s stock valued at $135,177,000 after purchasing an additional 810,364 shares during the last quarter. Wells Fargo & Company MN purchased a new stake in shares of Bioverativ during the 3rd quarter valued at about $124,500,000. Jackson Square Partners LLC increased its position in shares of Bioverativ by 21.1% during the 4th quarter. Jackson Square Partners LLC now owns 2,107,110 shares of the biotechnology company’s stock valued at $113,615,000 after purchasing an additional 366,503 shares during the last quarter. Finally, OppenheimerFunds Inc. increased its holdings in Bioverativ by 147.1% in the 4th quarter. OppenheimerFunds Inc. now owns 1,434,200 shares of the biotechnology company’s stock worth $77,332,000 after acquiring an additional 853,853 shares in the last quarter. Institutional investors and hedge funds own 97.18% of the company’s stock.
Bioverativ Inc (BIVV) opened at $104.98 on Monday. The company has a market capitalization of $11,360.00 and a P/E ratio of 38.31. Bioverativ Inc has a 52-week low of $48.14 and a 52-week high of $105.01.
Several equities research analysts recently issued reports on BIVV shares. William Blair reissued a “hold” rating on shares of Bioverativ in a report on Thursday. Royal Bank of Canada increased their target price on shares of Bioverativ to $68.00 and gave the stock a “market perform” rating in a report on Thursday, January 18th. Zacks Investment Research raised shares of Bioverativ from a “hold” rating to a “buy” rating and set a $60.00 target price for the company in a report on Monday, January 1st. Jefferies Group increased their target price on shares of Bioverativ to $79.00 and gave the stock a “buy” rating in a report on Thursday, January 18th. Finally, Raymond James Financial lowered shares of Bioverativ from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 23rd. Thirteen analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $63.15.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Receive News & Ratings for Bioverativ Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ and related companies with MarketBeat.com's FREE daily email newsletter.